Human immunome, bioinformatic analyses using HLA supermotifs and the parasite genome, binding assays, studies of human T cell responses, and immunization of HLA-A*1101 transgenic mice including novel adjuvants provide a foundation for HLA-A03 restricted CD8+T cell epitope based, adjuvanted vaccine protective against Toxoplasma gondii

Table 2 Predicted peptide candidates utilized for screening CD8+ T cells1

HLA-A*1101	ANTIGEN	PEPTIDE SEQUENCES	LENGTH	LOCATION	PREDICTED IC₅₀ nM	POOL
HLA-A*1101	GRA15	STSPFATRK	9	152-160	5	P1
HLA-A*1101	GRA15	ASTSPFATRK	10	150-159	18.2
HLA-A*1101	GRA10	AAAATPGLPK	10	568-577	9
HLA-A*1101	GRA10	AAATPGLPK	9	569-577	13.2
HLA-A*1101	GRA10	GVPAVPGLLK	10	507-516	17
HLA-A*1101	GRA10	SVVEENTMAK	10	865-874	25.1
HLA-A*1101	SAG2C	STFWPCLLR	9	13-21	9.3	P2
HLA-A*1101	SAG2C	ALLDHVFIEK	10	231-240	11.9
HLA-A*1101	SAG2C	SSPQNIFYK	9	290-298	12.9
HLA-A*1101	SAG2C	STTGVGETGK	10	163-172	28.4
HLA-A*1101	SAG2C	GTEYSLALK	9	136-144	35.4
HLA-A*1101	SAG2D	SSPQNIFYK	9	122-130	12.9
HLA-A*1101	SAG2D	ALLEHVFIEK	10	63-72	20.2	P3
HLA-A*1101	SAG2D	SSAQTFFYK	9	290-298	1.8
HLA-A*1101	SAG2D	TVYFSCDPK	9	154-162	5.3
HLA-A*1101	SAG2D	PSSAQTFFYK	10	289-298	17.9
HLA-A*1101	SAG3	VVGHVTLNK	9	80-88	15.4
HLA-A*1101	SAG3	KQYWYKIEK	9	145-153	19.3
HLA-A*1101	SRS9	TTCSVLVTVK	10	357-366	20.6	P4
HLA-A*1101	SRS9	AAASVQVPLK	10	140-149	29.9
HLA-A*1101	SRS9	AIQSQKWTLK	10	169-178	35
HLA-A*1101	BSR4	TTRFVEIFPK	10	284-293	10.3
HLA-A*1101	BSR4	VSGSLTLSK	9	83-91	21.1
HLA-A*1101	SPA	SSAYVFSVK	9	250-258	9.3	P5
HLA-A*1101	SPA	TSSAYVFSVK	10	249-258	12.2
HLA-A*1101	SPA	YVFSVKELPK	10	253-262	18
HLA-A*1101	SPA	KTEATYCYK	9	262-270	18.4
HLA-A*1101	SPA	MTLMITRDSK	10	195-204	25.5
HLA-A*1101	SPA	AVVSLLRLLK	10	89-98	6.5
HLA-A*1101	SPA	VVSLLRLLK	9	90-98	7.2
HLA-A*1101	MIC1	LTLTFISTK	9	338-346	13.8	P6
HLA-A*1101	MIC3	SVQLGSFDK	9	32-40	12.9
HLA-A*1101	MIC4	SAVWFGVAK	9	16-24	17.2
HLA-A*1101	MICA2P	GVMTPNQMVK	10	63-72	14.3

¹ Peptides derived from GRA10, GRA15, SAG2C, SAG2D, SAG2X, SAG3, SRS9, BSR4, SPA, MIC1, MICA2P were screened for potential supertype epitopes using the ARB algorithms from immunoepitope database at http://www.iedb.org/ on the basis of their predicted binding affinity to HLA-A*1101. A total of 34 unique peptides IC₅₀ < 50 nM (lower score, higher predicted binding affinity) of all ranked nonameric or decameric peptides were selected.